2. Search Result
Search Result
Results for "

F-ATP synthase

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

1

Recombinant Proteins

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128866
    TBAJ-876

    		Bacterial Infection
    TBAJ-876 is an orally active diarylquinoline anti-Mycobacterium agent. TBAJ-876 regulates energy metabolism by targeting the c and ε subunits of Mycobacterium tuberculosis F-ATP synthase, exerts bactericidal activity against replicating Mycobacterium tuberculosis, and retains activity against strains carrying the Rv0678 mutation. TBAJ-876 undergoes N-demethylation in vivo to form its major active metabolite TBAJ-876-M3, which has lower lipophilicity and hERG potassium channel binding affinity. TBAJ-876 is well tolerated in BALB/c mice and significantly reduces the colony-forming units of Mycobacterium tuberculosis in the lungs. In addition, TBAJ-876 exhibits inhibitory activity against Mycobacterium abscessus, reduces bacterial loads in the lungs and spleens of infected mice, and shows no antagonistic effect when used in combination with common antibiotics. TBAJ-876 can be used in studies related to tuberculosis and Mycobacterium abscessus pulmonary diseases .
    TBAJ-876
  • HY-161135A
    (rac)-TBAJ-5307

    		Bacterial Infection
    (rac)-TBAJ-5307 is the racemate of TBAJ-5307 (HY-161135). TBAJ-5307 is a broad spectrum anti-non-tuberculous mycobacteria inhibitor that can target the FO-domain of the engine and preventing rotation and proton-translocation .
    (rac)-TBAJ-5307
  • HY-162804
    ATP synthase inhibitor 3

    		Bacterial ATP Synthase Infection
    ATP synthase inhibitor 3 (compound PT6) is an orally active inhibitor of mycobacterial F-ATP synthase (IC50=0.788 μM). ATP synthase inhibitor 3 inhibits the growth of Mycobacterium tuberculosis H37Rv strain (ATCC-27294) in vitro and depletes intracellular ATP levels at an IC50 value of 30μM .
    ATP synthase inhibitor 3
  • HY-162028
    GaMF1.39

    		Bacterial Infection
    GaMF1.39 is an antimycobacterial compound, targeting the F-ATP synthase subunit γ. GaMF1.39 displays enhanced anti-tuberculosis activity in combination with ETC inhibitors .
    GaMF1.39
  • HY-161135
    TBAJ-5307

    		Bacterial Infection
    TBAJ-5307 is a broad spectrum anti-non-tuberculous mycobacteria inhibitor that can target the FO-domain of the engine and preventing rotation and proton-translocation. TBAJ-5307 inhibits non-tuberculous mycobacteria in vitro and in vivo .
    TBAJ-5307

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: